Notch-1 Regulates Akt Signaling Pathway and the Expression of Cell Cycle Regulatory Proteins Cyclin D1, CDK2 and P21 in T-ALL Cell Lines
Overview
Affiliations
Gain-of-function mutations in Notch-1 are common in T-cell lymphoblastic leukemia (T-ALL), making this receptor a promising target for drugs such as gamma-secretase inhibitors (GSIs). However, GSIs seem to be active in only a small fraction of T-ALL cell lines with constitutive Notch-1 activity and the downstream response of Notch signaling is only partially understood. To further investigate the molecular mechanisms underlying proliferation suppression and apoptosis and explore effective downstream target genes, we used RNA interference (RNAi) technology to down-regulate the expression of Notch-1 in GSIs-resistant T-ALL cell lines. Results showed that down-regulation of Notch-1 by transfection of a small interfering RNA (siRNA) could cause SupT1 cells proliferation inhibition by inducing G(0)/G(1) cell cycle arrest and apoptosis. The proliferation inhibitory and apoptotic effects resulting from down-regulation of Notch-1 may be mediated through regulating the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 and the activity of Akt signaling. In addition, our results demonstrated that down-regulation of Notch-1 signaling could sensitize SupT1 cells to adriamycin. Taken together, cell cycle regulatory proteins and Akt signaling may be attractive targets in T-ALL.
Wu L, Katsube T, Li X, Wang B, Xie Y Front Public Health. 2025; 13:1509675.
PMID: 39980929 PMC: 11839412. DOI: 10.3389/fpubh.2025.1509675.
Gonzalez Suarez N, Fernandez-Marrero Y, Hebert M, Roy M, Boudreau L, Annabi B Cancer Cell Int. 2023; 23(1):240.
PMID: 37833751 PMC: 10576371. DOI: 10.1186/s12935-023-03087-2.
Epithelial-to-Mesenchymal Transition-Related Markers in Prostate Cancer: From Bench to Bedside.
Gogola S, Rejzer M, Bahmad H, Abou-Kheir W, Omarzai Y, Poppiti R Cancers (Basel). 2023; 15(8).
PMID: 37190236 PMC: 10136789. DOI: 10.3390/cancers15082309.
HIV-1 exploits Hes-1 expression during pre-existing HPV-16 infection for cancer progression.
DSouza S, Mane A, Patil L, Shaikh A, Thakar M, Saxena V Virusdisease. 2023; 34(1):29-38.
PMID: 37009256 PMC: 10050651. DOI: 10.1007/s13337-023-00809-y.
Alhashem Z, Feldner-Busztin D, Revell C, Alvarez-Garcillan Portillo M, Camargo-Sosa K, Richardson J Elife. 2022; 11.
PMID: 35438077 PMC: 9129880. DOI: 10.7554/eLife.73550.